Singapore markets close in 1 hour 7 minutes

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2700+0.0900 (+7.63%)
At close: 04:00PM EST
1.2700 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.1800
Open1.2100
Bid0.0000 x 1000
Ask0.0000 x 1400
Day's range1.1600 - 1.3200
52-week range1.0600 - 556.8000
Volume551,402
Avg. volume891,262
Market cap4.421M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-157.0200
Earnings date14 Mar 2024 - 18 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est410.00
  • GlobeNewswire

    Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

    MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February

  • GlobeNewswire

    Panbela Announces Closing of Approximately $9.0 Million Public Offering

    MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a

  • GlobeNewswire

    Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

    MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins U